As mutations in the gene for Fms-like tyrosine kinase 3 (FLT3) are known to be important prognostic parameters in AML, we further analyzed PD-L1 impact in patient subcohorts divided according to FLT3 mutational status: 44 patients had wild-type FLT3 (subcohort denoted as FLT3-WT) and 39 patients had internal tandem duplications (subcohort FLT3-ITD), which are associated with unfavorable prognosis. This evidence concerns the gene FLT3 and acute myeloid leukemia.